在血液透析的第一年内,用糖氧化作为第一线酸盐结合剂进行血清管理
Juan A Medaura1, Meijiao Zhou2, Linda H Ficociello3
1Touro Infirmary, LCMC Health, New Orleans, Louisiana, USA.
在血液透析患者中,作为一线酸盐结合剂 (PB) 开始使用硫氧化 (SO),显著降低了血清水平. 这种方法还保持了较低的每日药片负担,改善了患者管理.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内部医学 内部医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖氧化 (SO) 是一种基于铁的酸盐结合剂 (PB),有效降低血清 (sP) 并减少药丸负担.
- 之前的研究主要集中在患有血液透析的患者;这项研究研究SO作为一线治疗事件患者.
研究的目的:
- 评估在血液透析的第一年内开始使用硫氧化 (SO) 作为一线酸盐结合剂 (PB) 的有效性和安全性.
主要方法:
- 对596名成年中心内血液透析患者的非识别数据的回顾性分析,在透析的第一年内规定了SO单疗法.
- 12个月持续使用SO的患者每季度分析血清 (sP) 的变化和达到目标水平 (≤5.5和≤4.5 mg/dL) 的情况.
- 评估了药丸负担,血清和完整的副甲状腺激素水平的变化.
主要成果:
- SO的启动与sP的季度显著下降有关 (平均0.26-0.36 mg/dL;p < 0.0001).
- 55-60%的患者达到sP ≤5.5 mg/dL,21-24%的患者达到sP ≤4.5 mg/dL.
- 每天的PB药片负担平均约为4片,血清和副甲状腺激素水平的良好变化.
结论:
- 在血液透析患者中第一线开始使用硫氧化 (SO) 有效地降低了血清 (sP).
- SO治疗提供了较低的药丸负担,并有助于在事件透析人群中实现控制目标.
更多相关视频
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
13:46Separation of Single-stranded DNA, Double-stranded DNA and RNA from an Environmental Viral Community Using Hydroxyapatite Chromatography
Published on: September 29, 2011
相关概念视频
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily...
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Oral Hypoglycemic Agents: Sulfonylureas
Renal Drug Excretion: Tubular Secretion
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
